Kyrgyzstan is about to get a much clearer picture of its population's defences against infectious disease. The country's Ministry of Health is teaming up with the St. Petersburg Pasteur Research Institute of Epidemiology and Microbiology to run a fresh phase of a large-scale seroepidemiological study — essentially, blood testing on a mass scale to measure antibody levels across the community.
The new phase runs from 2026 to 2028 and picks up where an earlier international project left off. That earlier round, carried out between 2023 and 2025, spanned five countries — Belarus, Kyrgyzstan, Armenia, Turkmenistan and Serbia — and drew 6,600 volunteer participants in Kyrgyzstan alone. Researchers measured antibodies against the pathogens behind measles, rubella, mumps, COVID-19 and viral hepatitis.
What did those tests show? Gaps. The results flagged insufficient immunity in certain population groups and pointed to a need to strengthen vaccination programmes. That is precisely what the next phase is designed to track: whether catch-up and supplementary vaccination campaigns are actually moving the needle, alongside fresh data on how widespread zoonotic and naturally occurring infections really are.
According to the Republican Health Promotion Center, the end goal is practical rather than academic — hard data that lets health officials forecast the epidemiological situation and plan both targeted and broader preventive measures. For a country where infectious disease monitoring has historically relied on reported cases rather than immunity surveys, this kind of longitudinal evidence is a meaningful step up.
For travellers, the relevance is indirect but real. Kyrgyzstan has become an increasingly popular destination for trekkers and horse-tour riders heading into the Tian Shan, and visitors routinely ask about health precautions. Large serosurveys like this one don't change the advice travellers already get — routine vaccinations up to date, measles protection in particular, plus sensible precautions around food, water and animals in rural areas — but they do signal a health system actively investing in disease surveillance. Watch for updated guidance as results come in through 2028, and always check current recommendations before a trip to Central Asia.
